Biologics | Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Biologics articles

Regulatory Rapporteur March 2026 – Contents

2026-03-06T09:18:00+00:00

The innovation era: Where biology meets technology
2026-03-05T17:58:00+00:00
Beyond product approval: Bridging the gap between regulatory success and patient access for biosimilars
2026-03-05T14:52:00+00:00
Navigating Advanced Therapy Medicinal Product regulatory changes: European Medicines Agency and UK guidance updates
2026-03-04T17:04:00+00:00
Cell therapy, gene therapy and tissue-engineered product manufacturing: Technical challenges, enablers and regulatory evolution
2026-03-04T15:08:00+00:00
Navigating regulatory pathways for live biotherapeutics in the US and EU: Challenges and opportunities
2026-03-04T12:15:00+00:00
FDA launches framework for accelerating development of individualised therapies for ultra-rare diseases
2026-02-26T15:22:00+00:00

PS1: Tailored development of biosimilars without efficacy and safety studies – Is this the future?
2025-11-18T09:58:00+00:00
HM9: From barrier to bridge – Practical strategies for successful advanced therapy medicinal product (ATMP) development
2025-11-18T09:57:00+00:00
HM4: Revision of the EU Variation Regulation – Continuing innovation in lifecycle management
2025-11-18T09:55:00+00:00
FDA comparability guidance: The impact of cell and gene therapy products
2025-07-11T10:26:00+01:00
Recent advances and the near-term outlook for Advanced Therapy Medicinal Products in cancer treatment
2025-05-02T13:41:00+01:00
Advanced therapies: A maturing regulatory framework
2025-05-02T13:40:00+01:00